RedHill Biopharma Ltd.

21 Ha'arba'a Street

Tel Aviv, 6473921, Israel

February 15, 2024

VIA EDGAR

United States Securities and Exchange Commission
Division of Corporation Finance

Office of Life Sciences

100 F Street N.E.
Washington, D.C. 20549

Attention: Tim Buchmiller

Re:	RedHill Biopharma Ltd. Registration Statement on Form F-1 Filed February 9, 2024 File No. 333-276979 (the “Registration Statement”)

Ladies and Gentlemen:

Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, RedHill Biopharma Ltd. (the “Company”) hereby respectfully requests that the effective date of the Company’s Registration Statement be accelerated by the Securities and Exchange Commission to 4:30 p.m., Eastern Time on February 15, 2024, or as soon thereafter as practicable.

The undersigned respectfully requests that it be notified of the effectiveness of the Registration Statement by telephone call to the Company’s counsel, Haynes and Boone, LLP, by calling Alla Digilova at (212) 659-4993, and that such effectiveness also be confirmed in writing.

	Very truly yours, REDHILL BIOPHARMA LTD.
	By:	/s/ Dror Ben-Asher Dror Ben-Asher Chief Executive Officer and Chairman of the Board of Directors

cc:	Rick A. Werner, Esq., Haynes and Boone, LLP
	Alla Digilova, Esq., Haynes and Boone, LLP